TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Barber HR, Sommers SC, Snyder R, Kwon TH (1975) Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol 121: 795–807
Barboule N, Mazars P, Baldin V, Vidal S, Jozan S, Martel P, Valette A (1995) Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 63: 611–615
Baselga J, Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 (Suppl 1): S35–S41
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091
Bookman MA, Darcy KM, Clarke-Pesrson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, transtuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 21: 283–290
Casalini P, Botta L, Ménard S (2001) Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 276: 12449–12453
Christian MC, Trimble EL (1994) Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 55 (Suppl): S143–S150
Cox DR (1972) Regression models and life tables. J Roy Stat Soc 34: 187–220
Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, Bernaudin JF, Riou G (1995) c-erbB2 gene amplification and protein expression in ovarian epithelial tumours: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 64: 146–151
Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B (1995) Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75: 2147–2152
Ferrandina G, Ranelletti OF, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G (2002) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85: 305–310
Graziano C (1998) HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today 12: 13–16
Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiammi-nedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575–4580
Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B (1999) Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 59: 3206–3214
Huang GC, Hobbs S, Walton M, Epstein RJ (2002) Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 86: 1104–1109
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17: 1983–1987
Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK (1992) NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol 44: 245–253
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kupryjanczyk J (2004) TP53 status determines prognostic and predictive factors in ovarian carcinomas. In Trends in Ovarian Cancer Research Bardos AP (ed) New York: Nova Science Publishers Inc., (in press)
Kupryjanczyk J, Dansonka-Mieszkowska A, Szymanska T, Karpinska G, Rembiszewska A, Rusin M, Konopinski R, Kraszewska E, Timorek A, Yandell DW, Stelmachow J (2000) Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction. Br J Cancer 82: 579–583
Kupryjanczyk J, Szymanska T, Mądry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska J (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEKI expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 88: 848–858
Lincet H, Poulain L, Remy JS, Deslandes E, Duigou F, Gauduchon P, Staedel C (2000) The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 161: 17–26
Meden H, Marx D, Rath W (1994) Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45–53
Meden H, Marx D, Roegglen T, Schauer A, Kuhn W (1998) Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 17: 61–65
Miller AB, Hogestraeten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–547
Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953–962
Press MF, Hung G, Godolphin W, Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771–2777
Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095–3105
Roche PC, Ingle JN (1999) Increased HER2 with US Food and Drug Administration-approved antibody. J Clin Oncol 17: 434 (letter)
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307–325
Rubin SC, Findstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO (1993) Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 168: 162–169
Russell P (1994) Surface epithelial–stromal tumors of the ovary. In Blaustein's Pathology of the Female Genital Tract Kurman RJ (ed) pp 705–782. Berlin, Heidelberg, New York: Springer-Verlag
Scambia G, Panici PB, Ferrandina G, Battaglia F, Baiocchi G, Di Stefano P, Tinari N, Coronetta F, Piantelli M, Natali P, Iacobelli S, Mancuso S (1993) Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynaecol Cancer 3: 271–278
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712
Tanner B, Kreutz E, Weikel W, Meinert R, Oesch F, Knapstein PG, Becker R (1996) Prognostic significance of c-erbB-2 mRNA in ovarian carcinoma. Gynecol Oncol 62: 268–277
Van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, de Vries EG (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70–78
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726
Xu F, Yu Y, Le XF, Boye C, Mills GB, Bast Jr RC (1999) The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5: 3653–3660